# RESPONDER-HF Trial

Study · id `cardio:ct-nct05425459` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05425459](<https://clinicaltrials.gov/study/NCT05425459>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05425459

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 750 participants.

## Technical summary

Registry record NCT05425459. Randomized; triple masking; primary purpose treatment. Start 2022-11-17 (actual); primary completion 2027-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 750 participants (planned count; ClinicalTrials.gov record NCT05425459, source copy `cardio:ctgov-nct05425459-2026-03-18`, retrieved 2026-10-26)
- Started: 2022-11-17 (actual) (ClinicalTrials.gov record NCT05425459, source copy `cardio:ctgov-nct05425459-2026-03-18`, retrieved 2026-10-26)
- Primary completion: 2027-07 (anticipated) (ClinicalTrials.gov record NCT05425459, source copy `cardio:ctgov-nct05425459-2026-03-18`, retrieved 2026-10-26)
- Completion: 2031-03 (anticipated) (ClinicalTrials.gov record NCT05425459, source copy `cardio:ctgov-nct05425459-2026-03-18`, retrieved 2026-10-26)
- Countries: United States; Australia; Austria; Belgium; Canada; Germany; Netherlands (ClinicalTrials.gov record NCT05425459, source copy `cardio:ctgov-nct05425459-2026-03-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05425459-2026-03-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: RESPONDER-HF Trial
- Condition: Heart Failure
- Condition: Heart Failure, Diastolic
- Intervention (Device): Corvia Atrial Shunt System / IASD System II
- Intervention (Other): Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)
- Lead sponsor: Corvia Medical
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart failure with mildly reduced or preserved ejection fraction (`cardio:hfpef`)

## Provenance

Content hash: 5299fe6bffc26b747c8a9ce49b1cc3c225a7d6d351072322b234360e7c9b902c
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
